Basic–liver, pancreas, and biliary tractInsulin Resistance Accelerates a Dietary Rat Model of Nonalcoholic Steatohepatitis
Section snippets
Animal Model and Experimental Design
Male Otsuka Long-Evans Tokushima Fatty (OLETF) rats, which have been established as an animal model of obese type 2 diabetes20, 21 were used as the experimental subjects (Otsuka Pharmaceutical, Tokushima, Japan). Male Long-Evans Tokushima Otsuka (LETO) rats, which originated from the same colony as OLETF rats by selective mating but did not develop diabetes, were used as control animals (Otsuka, Tokushima, Japan). Four-week-old OLETF and LETO rats were obtained and housed in a room under
Metabolic Parameters
Spontaneous-onset type 2 diabetes OLETF rats manifesting obesity and hyperinsulinemia from 8 weeks of age were compared with nondiabetic control LETO rats. NAFLD has been studied in OLETF rats because these animals show age-dependent increases of fat accumulation in the liver.27, 28 All rats in the OLETF group developed diabetes after 24 weeks of age (data not shown) as described previously.20, 21 Compared with LETO rats, OLETF rats fed a control diet manifested obesity (623 ± 11.4 g vs 504 ±
Progressive Insulin Resistance in Rats Fed MCD + HF Diet and Improved Insulin Sensitivity in Rats Fed MCD + PGZ Diet
Plasma insulin levels were similar between rats fed the MCD, MCD + HF, and MCD + PGZ diets (Table 1). Glucose tolerance tests (GTT) and ITT were conducted after 8 weeks in each group to evaluate insulin sensitivity (Figure 1). In the MCD diet group, blood glucose levels at 30 and 60 minutes increased significantly in OLETF rats compared with the LETO rats (P < .05) indicating that the obese diabetes background of OLETF rats induced postglucose hyperglycemia and insulin resistance (Figure 1A).
Insulin Resistance and Obese Diabetes Accelerate Pathology of Dietary Model of NASH
The MCD diet caused marked macrovesicular steatosis with focal lymphocytic infiltration and hepatocellular dropouts in LETO rats, whereas it caused intense lobular inflammation and perivenular and pericellular fibrosis prominently in zone 3 of the livers of OLETF rats at 8 weeks (Figure 2A–C). The MCD diet-induced steatosis and inflammation were more severe in OLETF rats than LETO rats at 4 weeks (P < .05, Figure 2C). The MCD+HF diet accelerated the severities of steatosis, inflammation, and
Insulin Resistance and Obese Diabetes Accelerate Liver Injury Along With Fat Accumulation in the Liver
Rats fed the MCD or MCD + HF diet showed macrovesicular steatosis in the liver (Figure 2A). Therefore, the hepatic triglyceride content was measured to evaluate the progression of steatosis quantitatively after 8 weeks (Figure 4A). The MCD and MCD + HF diet significantly increased hepatic triglyceride content in both LETO and OLETF rats (P < .05 vs the control diet). Hepatic triglyceride levels were more pronounced in OLETF than LETO rats (Figure 4A), although the degree of steatosis (%
Insulin Resistance and Obese Diabetes Activate Stellate Cells More Extensively in the Dietary Model of NASH
To investigate the activation of hepatic stellate cells, which play a central role in liver fibrosis, we performed an immunohistochemical analysis of α-SMA after 8 weeks. Representative photomicrographs of liver sections stained with anti-α-SMA antibody are shown in Figure 5. Activated stellate cells, which express α-SMA and therefore are also called myofibroblast-like cells, showed a prominent proliferation in the liver of rats fed the MCD diet. The activated stellate cells in MCD-OLETF rats
Insulin Resistance and Obese Diabetes Up-Regulate mRNA Expression of Fibrogenic and Lipogenic Genes
To clarify the mechanism by which the MCD diet caused hepatic fibrosis in rats, the expression of TGF-β, a master regulator of fibrogenesis, and its target genes collagen I and PAI-1 in the liver were estimated by quantitative real-time PCR (Figure 6A–C). The MCD diet up-regulated mRNA expression for TGF-β, collagen I, and PAI-1 in the livers of LETO rats (12.0-, 6.5-, and 3.9-fold, respectively, compared with the control diet, all P < .01) and further up-regulated expression in OLETF rats
Discussion
In this study, we focused on the pathophysiologic links between insulin resistance and the development of NASH. As reported previously, mice fed the MCD diet develop a malnutrition model of steatohepatitis without whole-body insulin resistance,30 probably due to decreased weight and adiposity in this model. Nevertheless, these mice demonstrate hepatic insulin resistance as evidenced by reduced tyrosine phosphorylation of insulin receptor substrate (IRS)-1 and IRS-2 and reduced phosphorylation
References (58)
Nonalcoholic steatohepatitis
Gastroenterology
(2001)- et al.
Prevalence of overweight in US children: comparison of US growth charts from the Centers for Disease Control and Prevention with other reference values for body mass index
Am J Clin Nutr
(2001) - et al.
Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association
Hepatology
(2002) - et al.
Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease
J Pediatr
(2003) - et al.
Association of nonalcoholic fatty liver disease with insulin resistance
Am J Med
(1999) - et al.
NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome
Hepatology
(2002) - et al.
Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome
Hepatology
(2003) - et al.
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
Gastroenterology
(2001) - et al.
Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis
J Hepatol
(2003) - et al.
Central role of PPAR-alpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice
Hepatology
(2003)
Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin
Gastroenterology
Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions
Am J Gastroenterol
The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance
J Hepatol
Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling
J Biol Chem
Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients
Hepatology
Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E
Hepatology
Steatohepatitis: a tale of two “hits”?
Gastroenterology
Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus
J Biol Chem
Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice
J Biol Chem
Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes
Cell Metab
Elevated stearoyl-CoA desaturase-1 expression in skeletal muscle contributes to abnormal fatty acid partitioning in obese humans
Cell Metab
Reduced adiposity and liver steatosis by stearoyl-CoA desaturase deficiency are independent of peroxisome proliferator-activated receptor-alpha
J Biol Chem
Regulation of extracellular matrix synthesis by transforming growth factor beta 1 in human fat-storing cells
Gastroenterology
The plasminogen-activating system in hepatic stellate cells
Hepatology
Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro
Gastroenterology
Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet
Biochem Biophys Res Commun
Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone
Hepatology
Pioglitazone prevents alcohol-induced fatty liver in rats through up-regulation of c-Met
Gastroenterology
Nonalcoholic fatty liver disease
N Engl J Med
Cited by (211)
Dapagliflozin improves steatohepatitis in diabetic rats via inhibition of oxidative stress and inflammation
2022, International ImmunopharmacologyC[sbnd]C chemokine ligand 3 deficiency ameliorates diet-induced steatohepatitis by regulating liver macrophage recruitment and M1/M2 status in mice
2021, Metabolism: Clinical and Experimental